Drug and Gene Delivery using Sonoporation for Cardiovascular Disease.
Using the improvements made in diagnostic contrast enhanced ultrasound, researchers have made significant progress in the field of ultrasound-mediated sonoporation for drug delivery. Many programs take advantage of commercial products; both ultrasound imaging systems and contrast agents to better enable translation from preclinical to first-in-man studies (Kotopoulis et al., Med Phys 40:072902, 2013). Particularly well-suited targets for this novel therapy are diseases of the cardiovascular system. This chapter will highlight several recent studies addressing treatment of both acute and chronic conditions.
Translational Sciences Lab, GE Global Research, Niskayuna, NY, USA. Castle@ge.com.
Jason
J
Castle
SonoGene LLC, Glen Ellyn, IL, USA. Steven_Feinstein@rush.edu.|Section of Cardiology, Rush University Medical Center, Chicago, IL, USA. Steven_Feinstein@rush.edu.
Steven B
SB
Feinstein
D000818:Animals; D002318:Cardiovascular Diseases / Q000628:therapy*; D003287:Contrast Media; D016503:Drug Delivery Systems; D018014:Gene Transfer Techniques; D006801:Humans; D045423:Microbubbles; D008863:Microspheres; D014465:Ultrasonics
D003287:Contrast Media
Cardiovascular; Contrast enhanced ultrasound (CEUS); Microbubble; Targeted drug delivery